The 3 most recent market catalysts affecting $KAPA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 65
Kairos Pharma Announces 1-For-7 Reverse Stock Split, Effective Sept. 1
Kairos Pharma announced a 1-for-7 reverse stock split, which will consolidate existing shares into fewer, higher-priced shares. This move is often undertaken by companies whose sto…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 75
Kairos Pharma Partners With Bayer To Mull ENV-105 Inhibitor In Combination With Bayer’s XOFIGO
Kairos Pharma (KAPA) has entered a strategic collaboration with Bayer to evaluate its lead antibody, ENV-105, in combination with Bayer's XOFIGO for metastatic castration-resistant…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 85
Kairos Pharma (KAPA) Stock Surges Over 22% After Hours: Why is it Moving?
Kairos Pharma (KAPA) reported that its lead cancer drug, ENV-105, showed a clean safety profile in a Phase 1 trial, with no serious adverse events among 13 patients. This is a cruc…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.